 Home > Active Ingredient News > Antitumor Therapy > JCO: The 5-year prognosis of first-line pembrolizumab for patients with metastatic NSCLC is significantly better than chemotherapy!

JCO: The 5-year prognosis of first-line pembrolizumab for patients with metastatic NSCLC is significantly better than chemotherapy!

 Last Update: 2021-04-22
 Source: Internet
 Author: User

Tags

phase 5 band

a refrigerator

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Historically, despite the use of platinum-based chemotherapy, the prognosis of patients with advanced non-small cell lung cancer ( NSCLC ) is still poor.

NSCLC

The KEYNOTE-024 study is an open-label, randomized controlled clinical trial that compared pembrolizumab and platinum-based chemotherapy for the proportion of previously untreated PD-L1 tumors with a score ≥50% and no EGFR Or the efficacy of ALK sensitivity variants in NSCLC patients, previous analyses have shown that pembrolizumab can significantly prolong the progression-free survival (PFS) and overall survival (OS) of patients .

Pembrolizumab can significantly prolong the progression-free survival (PFS) and overall survival (OS) of patients

This article reports the first 5-year follow-up results of the Phase III trial .

This article reports the first 5-year follow-up results of the phase III trial

In this trial, patients were randomly assigned to the pembrolizumab group (200 mg, 1 time/3 weeks, for 35 courses) or platinum-based chemotherapy group at 1:1 ratio.

A total of 305 patients were recruited: 154 were assigned to the pembrolizumab group and 151 were assigned to the chemotherapy group.

Kaplan-Meier assessment of OS and PFS in the two groups

Among the patients initially assigned to the chemotherapy group, 99 subsequently received anti-PD-1 or anti-PD-L1 treatment, and the effective crossover rate was 66.

The effective crossover rate was 66.

In summary, pembrolizumab as a first-line treatment for patients with metastatic NSCLC with PD-L1 tumor ratio score ≥50% can provide long-lasting clinically meaningful long-term OS benefits compared to chemotherapy .

Pembrolizumab is used as a first-line treatment for patients with metastatic NSCLC with PD-L1 tumor ratio score ≥50%.

Original source:

Reck Martin, Rodríguez-Abreu Delvys, Robinson Andrew G et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.